BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28830850)

  • 1. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
    Scheltema MJ; Postema AW; de Bruin DM; Buijs M; Engelbrecht MR; Laguna MP; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    Diagn Interv Radiol; 2017; 23(5):365-370. PubMed ID: 28830850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    van den Bos W; de Bruin DM; van Randen A; Engelbrecht MR; Postema AW; Muller BG; Varkarakis IM; Skolarikos A; Savci-Heijink CD; Jurhill RR; Zondervan PJ; Laguna Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    Eur Radiol; 2016 Jul; 26(7):2252-60. PubMed ID: 26449559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.
    Beyer LP; Pregler B; Nießen C; Michalik K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
    Clin Hemorheol Microcirc; 2016; 64(3):501-506. PubMed ID: 27935553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
    Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
    Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
    Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B
    Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI and CT in the follow-up after irreversible electroporation of small renal masses.
    Buijs M; de Bruin DM; Wagstaff PG; J Zondervan P; Scheltema MJ; W Engelbrecht M; P Laguna M; van Lienden KP
    Diagn Interv Radiol; 2021 Sep; 27(5):654-663. PubMed ID: 34559050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
    Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
    Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of irreversible electroporation of prostate cancer on microcirculation: Imaging findings in contrast-enhanced T1-weighted 3D MRI.
    Beyer LP; Pregler B; Verloh N; Brünn K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
    Clin Hemorheol Microcirc; 2017; 67(3-4):399-405. PubMed ID: 28885207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings.
    Niessen C; Jung EM; Beyer L; Pregler B; Dollinger M; Haimerl M; Scheer F; Stroszczynski C; Wiggermann P
    Clin Hemorheol Microcirc; 2015; 61(2):135-41. PubMed ID: 26410867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI-TRUS fusion for electrode positioning during irreversible electroporation for treatment of prostate cancer.
    Baur ADJ; Collettini F; Enders J; Maxeiner A; Schreiter V; Stephan C; Gebauer B; Hamm B; Fischer T
    Diagn Interv Radiol; 2017; 23(4):321-325. PubMed ID: 28508759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
    Scheltema MJ; Chang JI; van den Bos W; Böhm M; Delprado W; Gielchinsky I; de Reijke TM; de la Rosette JJ; Siriwardana AR; Shnier R; Stricker PD
    Eur Urol Focus; 2019 Jul; 5(4):585-591. PubMed ID: 29102671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
    Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
    Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome.
    Giganti F; Stabile A; Giona S; Marenco J; Orczyk C; Moore CM; Allen C; Kirkham A; Emberton M; Punwani S
    Magn Reson Imaging; 2019 May; 58():143-147. PubMed ID: 30768957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible Electroporation for the Ablation of Prostate Cancer.
    Karagiannis A; Varkarakis J
    Curr Urol Rep; 2019 Sep; 20(10):63. PubMed ID: 31478109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up after focal therapy of the prostate with high intensity focused ultrasound (HIFU) using contrast enhanced ultrasound (CEUS) in combination with MRI image fusion.
    Apfelbeck M; Chaloupka M; Schlenker B; Stief CG; Clevert DA
    Clin Hemorheol Microcirc; 2019; 73(1):135-143. PubMed ID: 31561350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
    Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
    JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound and Contrast-enhanced Ultrasound Findings after Percutaneous Irreversible Electroporation of Hepatic Malignant Tumors.
    Chai W; Xie L; Zhao Q; Cheng C; Tian G; Jiang T; Wu P
    Ultrasound Med Biol; 2020 Mar; 46(3):620-629. PubMed ID: 31924420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.